Jaguar Health to Discuss Phase 3 Trial Results in Virtual Chat

Jaguar Health, Inc. (NASDAQ:JAGX) is set to conduct a virtual fireside chat on June 10, 2025, as part of the Lytham Partners' Spring Spotlight Series. The discussion will focus on their recent meeting with the FDA regarding significant results from a Phase 3 trial. This trial analyzed a responder subgroup of breast cancer patients, showing promising outcomes.

The U.S. metastatic breast cancer population might be recognized as an orphan population, aligning with Jaguar Health's focus on orphan diseases. Consequently, the company plans to pursue expanded access for patients with breast cancer who may not qualify for pivotal trials involving their drug, crofelemer.